Aldeyra receives FDA Type A meeting minutes for reproxalap NDA; plans Type D meeting by Q3 2026

Aldeyra Therapeutics, Inc.

Received minutes from Type A meeting with FDA on June 10, 2026 regarding reproxalap NDA for dry eye disease.
Requested clarification of the minutes from FDA on July 15, 2026.
Intends to request a Type D meeting to discuss potential resubmission of the NDA.
Type D meeting expected to be held by the end of the third quarter of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.